KRAS and cancer: To determine whether JNK activation underlies the increased sensitivity of LKB1-deficient KRAS-mutant cancer cells to combined MAPK + MCL-1 inhibition, we used siRNA to simultaneously knock down both JNK1 and 2 isoforms in H2030 cells (Fig. S6I) and assessed the response to combined sotorasib or trametinib + AMG 176.